Overview of Mesar

Property	Description
Active Ingredient	Telmisartan (INN)
Primary Form	Oral Tablet
Pharmacological Class	Angiotensin II Receptor Blocker (ARB)
Rx/OTC Status	Prescription Only (Rx)
Manufacturer Focus	Cardiovascular disease management

What Type of Compound is Mesar?

Mesar is a brand name for a pharmaceutical compound whose active component, Telmisartan, belongs to the class of Angiotensin II Receptor Blockers (ARBs). It is a prescription-only (Rx) medication used widely in the long-term management of cardiovascular health.

As a small-molecule, synthetic agent, Telmisartan functions as a potent regulatory therapy. Telmisartan is recognized for its high affinity and long duration of binding to its target receptor, ensuring consistent regulatory action over the full 24-hour dosing period. This sustained action is a key differentiating feature, allowing for effective control across the full day and night.

Mesar’s Core Composition and Form

The core of Mesar is the active ingredient Telmisartan (INN), a precise chemical entity presented as a simple, stable tablet intended for oral administration. Telmisartan is structurally distinct from earlier ARBs, possessing properties such as high fat-solubility (lipophilicity).

This high lipophilicity is a distinctive feature of Telmisartan among ARBs. This lipophilic nature allows Telmisartan to penetrate tissues effectively, offering therapeutic benefits that extend beyond simple blood pressure control. The consistency of the tablet form provides a reliable delivery method for daily, foundational support.

What is Mesar Used for? (General Purpose)

Mesar is generally utilized to provide foundational support for long-term cardiovascular health, most notably by helping patients maintain healthy blood pressure levels. A typical use scenario involves an adult patient taking the medication once daily to reduce the overall strain on their heart and blood vessels.

Beyond its primary role as an ARB, Telmisartan has a unique capacity to interact with the PPAR-gamma receptor, a supplementary action that is distinguishing among ARBs. The overall therapeutic goal remains focused on maintaining the integrity and healthy functioning of the circulatory system.

What side effects are possible with Mesar?

Possible Side Effects and Safety Information

The safety profile of Mesar, which contains the active ingredient Telmisartan, is structured around standardized regulatory classifications of potential adverse reactions and specific usage constraints, as documented in official government sources.

Adverse effects are grouped by frequency and the System-Organ Class (SOC) they affect, covering categories such as Infections and Infestations, Gastrointestinal Disorders, and Musculoskeletal and Connective Tissue Disorders.

Frequency-Classified Adverse Reactions

Classification	Examples of Reactions
Common (ge1/100 to <1/10)	Upper respiratory tract infections, dizziness, back pain.
Uncommon (ge1/1,000 to <1/100)	Anemia, hyperkalaemia, hypotension, cough, renal impairment, asthenia.
Rare (ge1/10,000 to <1/1,000)	Sepsis (including fatal outcome), anaphylactic reaction, angioedema (including fatal outcome), rhabdomyolysis.

Key Safety Constraints and Patterns

The regulatory profile identifies specific safety constraints. Mesar is contraindicated during the second and third trimesters of pregnancy due to a documented risk of fetal toxicity, and in patients with severe hepatic impairment or biliary obstructive disorders. Usage in diabetic patients who are also taking Aliskiren is also a contraindication.

Specific time-related safety patterns are noted: Symptomatic hypotension may occur, particularly after the first dose in individuals who are volume- or salt-depleted. Additionally, the label requires the periodic monitoring of serum creatinine and potassium levels in susceptible individuals, such as those with renal impairment. These classifications establish the non-instructional regulatory boundaries and known risks of the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Mesar (Telmisartan) describes the manifestations of overdose as being primarily related to its effect on the cardiovascular system.

Documented Overdose Manifestations

Overdose may result in pronounced hypotension (clinically low blood pressure), often accompanied by symptoms such as dizziness or fainting. Changes in heart rate are also documented, including tachycardia (fast heart rate) or, less commonly, bradycardia (slow heart rate).

Required Emergency Actions

Immediate medical attention must be sought if an overdose is suspected. Urgent medical assistance is specifically required if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management is strictly symptomatic and supportive. Regulatory labeling advises that if symptomatic hypotension occurs, the patient should be placed in the supine position, and an intravenous infusion of normal saline may be administered. It is officially stated that no specific antidote is known, and Telmisartan is not removed by hemodialysis.

Population Considerations

Specific monitoring is noted for infants with in utero exposure, who must be closely observed for potential adverse effects including hypotension, hyperkalemia, and oliguria.

Therapeutic Uses of Mesar

What Mesar Treats: Main Uses and Benefits

Mesar is commonly used to help manage conditions associated with systemic or localized discomfort and is applied across domains where additional symptomatic support is needed.

This medication is relevant for easing certain symptoms related to heightened physiological activity, functional stress, and systemic imbalance. Mesar is considered appropriate for use in clinical settings that involve acute or unstable symptom patterns, such as those associated with conditions characterized by periods of heightened symptoms and episodic or fluctuating manifestations.

When symptoms intensify and supportive relief is needed, Mesar helps address symptom clusters that may become intense or disruptive. It helps maintain a sense of stability when symptoms are more noticeable, assists with maintaining functional stability, and contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Episodic Discomfort

Mesar is often used during phases where symptoms lead to temporary functional strain or discomfort, providing support that helps ease the overall symptom burden.

Regulatory References

NHS Scotland guidance on Telmisartan

Eligibility and Restrictions for Use

Who Can and Cannot Use Mesar?

The eligibility for Mesar (Telmisartan) is strictly defined by regulatory authorities and limits use based on a patient’s physiological state, age, and pre-existing medical conditions. The medicine is formally contraindicated in several key populations.

Absolute Contraindications (Must Not Use)

Mesar is formally prohibited in the following groups, as stated in official regulatory labels:

Patients with known hypersensitivity (e.g., angioedema) to Telmisartan or any component.
Pregnant women in the second and third trimesters. Treatment must be stopped immediately upon detection of pregnancy.
Individuals with severe hepatic impairment, cholestasis, or biliary obstructive disorders.
Diabetic patients or those with severe renal impairment who are concurrently receiving aliskiren.

Conditional Use and Age-Group Limitations

Use of Mesar is established only in the adult population. Safety and efficacy are not established in the pediatric population (under 18 years); therefore, use is not recommended in children and adolescents. Patients with mild to moderate hepatic impairment or severe renal impairment require special caution and may face limits on the maximum authorized dose (posology). Mesar is also not recommended for use by breastfeeding mothers.

What should I know about interactions with other medicines?

Mesar Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Mesar (Telmisartan) as stated in authoritative government drug labels.

Documented Interaction Restrictions

Co-administration with Aliskiren is formally contraindicated in patients with a diagnosis of diabetes mellitus or those presenting with moderate-to-severe renal impairment (Glomerular Filtration Rate, GFR < 60 mL/min/1.73 m^2). This restriction addresses the increased risk of adverse outcomes from Dual RAAS Blockade.

Use of Mesar with Angiotensin-Converting Enzyme (ACE) Inhibitors is officially not recommended due to the additive pharmacodynamic effects and associated increase in the risk of hypotension, hyperkalemia, and reduced renal function.

Exposure-Modifying and Pharmacodynamic Effects

Mesar is documented to increase the plasma concentration of co-administered Digoxin, resulting in a significant rise in both peak (Cmax) and trough (Cmin) levels. Co-administration with Lithium leads to a reversible increase in serum Lithium concentrations and documented toxicity, due to decreased renal clearance of Lithium.

Substances that increase potassium levels, including potassium-sparing diuretics and potassium supplements, pose an increased risk of hyperkalemia (high potassium levels) due to additive effects on the RAAS. Additionally, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may attenuate the blood pressure-lowering effect of Telmisartan and increase the risk of worsening renal function, particularly in elderly or volume-depleted patients. No mandatory timing separation rules are specified in the official labels for Mesar.

Mechanism of Action

Mesar (Telmisartan) acts through a dual pharmacodynamic mechanism to modulate cardiovascular and metabolic pathways at the molecular level. Its primary action is the selective, high-affinity antagonism of the Angiotensin II Type 1 (AT1) receptor. By blocking this receptor, the drug suppresses the signaling sequence of the Renin-Angiotensin-Aldosterone System (RAAS) that drives vasoconstriction and aldosterone release. This interruption modifies the early molecular steps that shape systemic physiological outcomes, resulting in the relaxation and widening of peripheral blood vessels and a reduction in fluid volume.

The mechanism's duration is tied to its slow dissociation kinetics from the AT1 receptor, ensuring continuous blockade over a 24-hour period. A distinct secondary action involves partial agonism of the nuclear receptor Peroxisome Proliferator-Activated Receptor gamma (PPAR-gamma). This partial activation influences metabolic pathways and the regulation of inflammatory processes within the vessel walls, contributing a secondary action to the observed physiological effects.

Dosage and Administration Information

How to use Mesar

The administration of Mesar (Telmisartan) follows protocols for its role as a long-term cardiovascular therapy. The drug is exclusively formulated as an Oral Tablet and must be taken by mouth once daily. Consistent daily dosing is key to maintaining its sustained action over the full 24-hour interval.

Official Administration Guidelines

Entity	Instruction
Route of administration	Oral (by mouth)
Official Tablet Strengths	20 mg, 40 mg, and 80 mg
Dosing schedule (Adults)	Standard starting dose is 40 mg once daily, adjusted up to a maximum of 80 mg once daily.
Frequency and Timing	Must be taken once daily; best taken at the same time each day.
Timing in relation to meals	Can be administered with or without food.
Preparation requirements	Swallow the tablet whole with liquid.

Procedural and Population Constraints

The tablet must be kept in its sealed blister pack until immediately before ingestion due to its sensitivity to moisture. Regarding specific patient groups, the dose for those with hepatic impairment (liver function limitations) must not exceed 40 mg once daily. No initial dosage adjustment is typically required based on age or for those with renal impairment. If a dose is missed, patients should simply take the next scheduled dose at the regular time, omitting the missed dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Mesar

Evidence for use in High Blood Pressure

The evidence base for Mesar (Telmisartan) includes numerous Randomized Controlled Trials (RCTs) and systematic reviews, which often synthesize findings from multiple RCTs. These studies were evaluated in adults with high blood pressure, including those with co-existing conditions like diabetes. Research examined changes in both the top and bottom numbers of the blood pressure reading and reported measured patterns over a full 24-hour period. When comparing Mesar with other similar medications, findings were mixed due to statistical variability in the absolute measured changes, and certain comparative evidence is lacking.

Evidence for Reduction of Cardiovascular Events

Mesar was evaluated in large-scale, long-term clinical trials focusing on outcomes describing episodic or acute changes related to cardiovascular health, such as cardiovascular death, stroke, and non-fatal heart attack. Studies monitored these events in populations including older adults and those with existing cardiovascular disease or diabetes with additional risk factors. While data show patterns related to these outcomes, in some specific high-risk cohorts, a statistically significant difference was not observed for every single outcome evaluated in the primary analysis.

Evidence in High-Risk Populations and Uncertainties

Research has explored the use of Mesar in patients with Type 2 diabetes, observing outcomes related to systemic or functional imbalance, specifically how markers like albuminuria evolved over time. This evidence is largely derived from subgroup analyses of larger trials. The certainty for long-term renal outcomes (such as progression to dialysis) remains low because these were not the primary focus of the initial studies. Data are still emerging for long-term renal endpoints, and there is limited information regarding Mesar's use in the pediatric population.

Key Studies & References Telmisartan: an update on its therapeutic status in the management of hypertension with a focus on its renoprotective effects

Frequently Asked Questions (FAQ)

Common questions about Mesar (FAQ)

Q: Is it normal to feel a little dizzy when starting Mesar?

A: Regulatory documents indicate that dizziness is a common adverse reaction reported by patients taking Mesar. These symptoms are often observed during the initial phases of treatment and are typically related to a reduction in blood pressure (hypotension).

Q: Can Mesar affect my sleep?

A: Official product information notes that insomnia (difficulty sleeping) has been reported as an uncommon adverse reaction in clinical trials of Mesar. Persistent sleep issues are a symptom that should be addressed by a healthcare provider.

Q: Are there any major food restrictions while taking Mesar?

A: Mesar can be taken with or without food. However, official patient information includes a warning about the use of potassium-containing salt substitutes or over-the-counter potassium supplements, as these can increase the risk of high potassium levels (hyperkalemia).

Q: Does Mesar interact with over-the-counter pain relievers like ibuprofen?

A: Official labeling confirms an interaction. Taking Mesar with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may reduce Mesar's ability to lower blood pressure. The combination has also been associated with an increased risk of worsening kidney function, especially in certain patient groups.

Q: Can Mesar cause a persistent dry cough like some other heart medications?

A: Official product information lists cough as an uncommon adverse reaction. Regulatory documents do not typically characterize this cough as 'persistent' or 'dry,' which are traits commonly associated with a different class of blood pressure medicine.

Q: Can I take Mesar with my vitamins and supplements?

A: Regulatory medication guides note that a prescribing doctor and pharmacist should be informed about all other products taken, including vitamins, herbal products, and dietary supplements. This is important because certain supplements, particularly those affecting potassium levels, may interact with Mesar.

Q: What does the research say about Mesar's effectiveness compared to placebo?

A: Clinical studies found that Mesar demonstrated a reduction in blood pressure when compared to an inactive placebo. The regulatory data confirms measurable blood pressure reduction is achieved across the approved dose range.

Q: Do I need to avoid potassium-rich foods while on Mesar?

A: Since Mesar can increase potassium levels in the blood (hyperkalemia), the official warnings focus primarily on supplements and salt substitutes. Because of this risk, the decision regarding the consumption of high-potassium foods should be guided by a healthcare provider.

Q: Is Mesar safe for people with diabetes?

A: Mesar has been used in patients with Type 2 diabetes to help reduce cardiovascular risks. However, a specific warning prohibits its use in diabetic patients who are also taking the medication aliskiren.

Q: Does Mesar cause fatigue or tiredness?

A: Regulatory documents list both fatigue (a feeling of general tiredness) and asthenia (physical weakness or lack of energy) among the reported adverse reactions in patients taking Mesar.

Q: Does Mesar change the heart rate?

A: Official adverse event lists indicate that Mesar may affect heart rate in some people. Both bradycardia (uncommonly slow heart rate) and tachycardia (rarely fast heart rate) have been reported as cardiac disorders in clinical experience with the drug.

Q: Does taking Mesar affect my cholesterol levels?

A: Clinical trial data sometimes report hypercholesterolemia, which is an elevation of cholesterol levels, as an uncommon finding in some patients using Mesar.

Q: Are there any studies on Mesar use in children or adolescents?

A: The safety and effectiveness of Mesar have not been established in the pediatric population (patients under 18 years of age). Therefore, the medication is generally not recommended for use in children and adolescents.

Q: Is Mesar prescribed for conditions other than hypertension?

A: Yes, in addition to treating high blood pressure (hypertension), Mesar is officially approved to reduce the risk of serious cardiovascular events like stroke or heart attack in certain high-risk patients 55 years and older.

Q: What effect does grapefruit juice have on Mesar?

A: Some regulatory medication guides note that the consumption of grapefruit or grapefruit juice should be discussed with a pharmacist or doctor during treatment, as it may affect how the body processes the medication.

Q: Is Mesar a diuretic (water pill)?

A: Mesar is officially classified as an Angiotensin II Receptor Blocker (ARB), not a diuretic or 'water pill.' However, it is very commonly prescribed as part of a combination pill that includes a diuretic like hydrochlorothiazide.

Q: Why do doctors often prescribe Mesar for heart conditions?

A: The drug is prescribed for heart conditions because it is approved for both the treatment of high blood pressure and for reducing the risk of serious cardiovascular events in high-risk patients. Its mechanism of action helps lessen the overall strain on the heart and blood vessels.

Q: Will Mesar affect my ability to drive or operate machinery?

A: Official safety information indicates that caution is warranted when driving or operating machinery. This is because Mesar may cause side effects such as dizziness, syncope (fainting), or somnolence (drowsiness), which could affect concentration and safe operation.

Q: Are there any natural products or herbs that interact negatively with Mesar?

A: Patients should inform their doctor about all herbal products and natural supplements they are taking. This is particularly important for products that could influence blood pressure or potassium levels, as they may create an unwanted additive effect with Mesar.

Q: Why is Mesar sometimes given with other medications for high blood pressure?

A: Mesar is often given with other blood pressure medications, such as diuretics or calcium channel blockers, to achieve an additive blood pressure-lowering effect. This strategy is used when a patient’s blood pressure is not adequately controlled with a single medication alone.

Q: Is it safe to consume alcohol in moderation while taking Mesar?

A: Official patient safety materials indicate that alcohol can enhance the blood pressure-lowering effect of Mesar. Combining the two may have additive effects that increase the risk of symptoms like headache, dizziness, and fainting.

Q: What is the shelf life of Mesar tablets?

A: According to product information, Mesar (Telmisartan) tablets typically have a shelf life of 24 months from the date they are manufactured. This is valid only if they are stored properly at the required controlled room temperature and kept in the original, sealed packaging.

Q: Can Mesar cause swelling in the ankles or feet?

A: Official adverse reaction reports include peripheral edema (swelling in the hands, ankles, or feet) in the clinical trial data for Mesar.

How should Mesar be stored and disposed of?

How to Store and Dispose of Mesar

The storage and handling of Mesar (telmisartan) tablets are governed by regulatory requirements to ensure product stability and safety.

Storage Requirements

Mesar must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with protection from excessive heat and freezing. The tablets are sensitive to moisture and must be stored in the original, sealed blister packaging and removed only shortly before administration. This protection is mandatory due to the hygroscopic nature of the medicine. Always keep Mesar out of the sight and reach of children.

Disposal Instructions

Expired or unused Mesar must not be disposed of via wastewater or the sanitary sewer system, as the product is environmentally toxic. Disposal must adhere to local regulations for unused medicines, typically requiring the return of the product to an approved take-back program or waste disposal facility.

Mesar